On July 31, Lilly publicized the findings of the Phase 3 SURPASS-CVOT study, marking the inaugural direct comparison of cardiovascular outcomes between two incretin-based medications. This pivotal study underscores the clinical significance of Lilly's innovative drug, tirzepatide, in safeguarding cardiovascular and renal health for patients with type 2 diabetes. Encompassing over 13,000 participants and spanning 4.5 years, the research revealed that tirzepatide demonstrated non-inferiority to dulaglutide in mitigating the risk of major adverse cardiovascular events, while also enhancing glycated hemoglobin levels, body weight management, renal function, and all-cause mortality indicators.